BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Month: September 2021

5 posts
Xontogeny-CEO-Chris-Garabedian-Interiew-BioTech-Health-X
BioTech Health X
  • September 29, 2021

BioTech CEO InterviewsXontogeny CEO Chris Garabedian Exclusive Interview [September 2021]

  • 5 minute read
As we expand our coverage of the biotechnology sector with the latest biotech news, our team at BioTech…
0 Shares
0
0
0
0
0
0
0
MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
Jak Thomson
  • September 7, 2021

Biotech NewsMacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients

  • 3 minute read
Biopharma MacroGenics, Inc. (NASDAQ: MGNX) announced that the final overall survival (OS) analysis did not demonstrate a statistically…
0 Shares
0
0
0
0
0
0
0
Infinity Pharmaceuticals Add 2 New Members to Board of Directors
BioTech Health X
  • September 7, 2021

Biotech NewsInfinity Pharmaceuticals Add 2 New Members to Board of Directors

  • 3 minute read
Clinical-stage biotech Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced the change of 2 new Board of Directors roles including…
0 Shares
0
0
0
0
0
0
0
Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
Jak Thomson
  • September 7, 2021

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

  • 10 minute read
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
0 Shares
0
0
0
0
0
0
0
Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)
BioTech Health X
  • September 3, 2021

Biotech NewsCapricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)

  • 4 minute read
Capricor Therapeutics Announces HOPE-2 Trial Data Presentation On September 2nd, Capricor Therapeutics (NASDAQ: CAPR) announced an upcoming company…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
  • Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
  • SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 19, 2022
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    • September 14, 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 3, 2022
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    Mayo-Clinic-Gene-Accelerator
    • September 2, 2022
    SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
    SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
    • August 1, 2022
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • July 28, 2022
  • Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    • July 22, 2022
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • July 20, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech News (44)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top